

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application 10/522,426		Our File No. P/2107-264		
		Applicant Ferdinand Hermann Bahlmann, et al.				
		Filing Date March 25, 2006		Group Art Unit 1654		
U.S. PATENT DOCUMENTS (not submitted for applications filed after 6/30/03)						
Examiner Initial	Document Number	Date MM-YYYY	Name	Class	Sub-class	Filing Date If Appropriate
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
FOREIGN PATENT DOCUMENTS						
	Document Number	Date MM-YYYY	Country	Class	Sub-class	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
17		Japanese Office Action mailed March 9, 2010 in corresponding Japanese Patent Application No. 2004-525322 (English language).				
17		Montini, G., et al. "Pharmacokinetics and Hematologic Response to Subcutaneous Administration of Recombinant Human Erythropoietin In Children Undergoing Long-Term Peritoneal Dialysis: A Multicenter Study," J. Pediatr., 1993, Vol. 122, No. 2, pp. 297-302.				
17		Matuszkiewicz-Rowinska, J., et al., "Effect of Low-Dose Recombinant Humane Erythropoietin Therapy On The Quality Of Life In Patients With Anemia In The Course of End-Stage Renal Failure Treated With Dialysis," Pol Arch Med Wewn, 1996, Vol. 96, No. 2, pp. 143-52 (Abstract), Medline [online], Accession No. 1997240098, PubMed ID 9122002.				
Examiner <i>CS</i>		Date Considered <i>4/28/10</i>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						